The estimated Net Worth of Christopher Ray Aker is at least $835 Tysiąc dollars as of 18 January 2024. Mr. Aker owns over 5,468 units of Regulus Therapeutics Inc stock worth over $15,486 and over the last 6 years he sold RGLS stock worth over $31,158. In addition, he makes $787,907 as Senior Vice President i General Counsel at Regulus Therapeutics Inc.
Sign up
Mr. Aker RGLS stock SEC Form 4 insiders trading
Christopher has made over 14 trades of the Regulus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,468 units of RGLS stock worth $6,507 on 18 January 2024.
The largest trade he's ever made was selling 6,950 units of Regulus Therapeutics Inc stock on 14 May 2019 worth over $9,800. On average, Christopher trades about 1,204 units every 73 days since 2019. As of 18 January 2024 he still owns at least 10,056 units of Regulus Therapeutics Inc stock.
You can see the complete history of Mr. Aker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Aker biography
Christopher Ray Aker J.D. serves as Senior Vice President, General Counsel of the Company. Christopher Aker has served as our Senior Vice President and General Counsel since January 2019, and before that served as our Senior Director, Legal Affairs since February 2011. Prior to joining us, Mr. Aker served as the Senior Director, Administration and Senior Corporate Counsel for Phenomix Corporation, a privately-held biopharmaceutical company, and was responsible for operational and legal oversight. Prior to Phenomix, Mr. Aker was Senior Corporate Counsel at SUGEN, Inc., a wholly-owned subsidiary of Pharmacia, until its acquisition by Pfizer. Prior to SUGEN, Mr. Aker was in private practice with various law firms. Mr. Aker received his Bachelor of Arts degree in International Relations from the University of California, Davis and his J.D. from Santa Clara University.
What is the salary of Christopher Aker?
As the Senior Vice President i General Counsel of Regulus Therapeutics Inc, the total compensation of Christopher Aker at Regulus Therapeutics Inc is $787,907. There are 2 executives at Regulus Therapeutics Inc getting paid more, with Joseph Hagan having the highest compensation of $2,014,280.
How old is Christopher Aker?
Christopher Aker is 59, he's been the Senior Vice President i General Counsel of Regulus Therapeutics Inc since 2019. There are 5 older and 10 younger executives at Regulus Therapeutics Inc. The oldest executive at Regulus Therapeutics Inc is David Baltimore, 82, who is the Independent Director.
What's Christopher Aker's mailing address?
Christopher's mailing address filed with the SEC is 10614 Science Center Dr, San Diego, CA 92121, USA.
Insiders trading at Regulus Therapeutics Inc
Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.
What does Regulus Therapeutics Inc do?
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
What does Regulus Therapeutics Inc's logo look like?
Complete history of Mr. Aker stock trades at Regulus Therapeutics Inc
Regulus Therapeutics Inc executives and stock owners
Regulus Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joseph Hagan,
President, Chief Executive Officer, Director -
Joseph P. Hagan M.B.A.,
Pres, CEO & Director -
Christopher Aker,
Senior Vice President, General Counsel -
Christopher Ray Aker J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Crispina Calsada,
Chief Financial Officer -
Crispina Calsada,
Chief Financial Officer -
Stelios Papadopoulos,
Independent Chairman of the Board -
Pascale Witz,
Independent Director -
Simos Simeonidis,
Independent Director -
Hugh Rosen,
Independent Director -
William Rastetter,
Independent Director -
Jake Nunn,
Independent Director -
Kathryn Collier,
Independent Director -
David Baltimore,
Independent Director -
Denis Drygin,
Chief Scientific Officer -
Firuz Shakoori,
Head of CMC -
Turner Jenkins,
Sr. Director of Corp. Devel. -
Dr. Denis Drygin Ph.D.,
Chief Scientific Officer -
Daniel J. Penksa,
Controller & Principal Accounting Officer -
Jason Raleigh Nunn,
-
Daniel R. Chevallard,
Chief Financial Officer -
Paul C Grint,
President & CEO -
Douglas E Williams,
Director -
Mark Albert Deeg,
Chief Medical Officer -
Pharmaceuticals, Inc. Alnylam,
10% owner -
Mark G Foletta,
Director -
Timothy Michael Wright,
Chief R & D Officer -
Alexander J Sarissa Capital...,
-
Plcastrazeneca Ab Astrazeneca,
-
David Leslie Szekeres,
Chief Business Officer & GC -
Paul Edward Walker,
-
Peter J Barris,
10% owner -
Anthony A. Jr. Florence,
-
Scott D Sandell,
-
David M Mott,
10% owner -
Mohamad Makhzoumi,
-
Equity Opportunities V, Llc...,
-
Ali Behbahani,
-
Neil W Gibson,
Chief Scientific Officer -
Pharmaceuticals Incparshall...,
-
Kleanthis G Xanthopoulos,
President and CEO -
Pharmaceuticals Inc Ionis,
10% owner -
Bruce L A Carter,
Director -
Barry E Greene,
Director -
Sanofi,
10% owner -
B Lynne Parshall,
Director -
Stanley T Crooke,
Director -
John Maraganore,
Director -
Garry E Menzel,
COO & Executive VP, Finance -
Forest Baskett,
-
Carmen Chang,
-
Joshua Makower,
-
Peter W. Sonsini,
-
Capital Offshore Master Fun...,
10% owner -
Alice Shih Hou Baltimore Da...,
-
Alice Shih Hou Huang,
-
Preston Klassen,
President & Head of R & D